HPS0317
1) 非営利機関以外の利用者は事前に<a href= 'http://ips-cell.net/j/index.php' target="_blank">iPSアカデミアジャパン株式会社 </a>から確認書を得ること。2) 寄託者から承諾を得ること。3) 寄託者との共同研究を条件とすること。4) 先ずは、<a href="mailto:cellips.brc@riken.jp?subject=Disease specific iPS cell line 問い合わせ&">理研細胞バンク</a>にお問い合わせください 。
疾患特異的iPS細胞株。デュシェンヌ型筋ジストロフィー症候性キャリア患者由来。HPS0319、HPS0322、HPS0323と同一人由来。骨格筋組織の中の線維芽細胞にレトロウイルスベクターにより5因子（Oct3/4, Sox2, Klf4, Nanog, LIN28）を導入して樹立。<a href='http://cell.brc.riken.jp/ja/manual/vitrification' target="_blank">ガラス化法（Vitrification法）</a>保存。
HPS0317
Disease specific iPS cell line derived from a patient : Muscular dystrophy, Duchenne type (manifesting carrier). The source of this cell line is fibroblasts derived from skeletal muscle tissue. HPS0319, HPS0322 and HPS0323 were derived from the same patient. Order Form (C-0042, C-0057, C-0007 or C-0007p).
1) In relation to the for-profit organizations, please contact <a href= 'http://ips-cell.net/e/index.php' target="_blank">iPS Academia Japan, Inc.</a>, prior to the utilization of iPS cells. 2) The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. 3) Collaboration with the depositor is necessary. 4) Contact Us : <a href="mailto:cellips.brc@riken.jp?subject=Disease specific iPS cell line&">RIKEN Cell Bank</a>
疾患特異的iPS細胞株。デュシェンヌ型筋ジストロフィー症候性キャリア患者由来。HPS0317, HPS0318, HPS0319, HPS0320, HPS0321, HPS0322, HPS0323, HPS0324, HPS0325は同一人由来。骨格筋組織の中の線維芽細胞にレトロウイルスベクターにより5因子（Oct3/4, Sox2, Klf4, Nanog, LIN28）を導入して樹立。<a href='https://cell.brc.riken.jp/ja/manual/vitrification' target="_blank">ガラス化法（Vitrification法）</a>保存。
Disease specific iPS cell line derived from a patient : Muscular dystrophy, Duchenne type (manifesting carrier). The source of this cell line is fibroblasts derived from skeletal muscle tissue. HPS0317, HPS0318, HPS0319, HPS0320, HPS0321, HPS0322, HPS0323, HPS0324, HPS0325 were derived from the same patient.